Anesiva wins FDA approval to expand pain drug indication

Zingo powder intradermal injection system was previously approved to treat the pain associated with peripheral IV insertions and blood draws in children three to 18 years of age. The notification was received according to Prescription Drug User Fee Act deadlines.

As announced earlier, Anesiva ceased Zingo commercial activities to focus on the development of Adlea, its novel non-opioid, long-acting analgesic drug candidate for the management of acute pain following orthopedic surgeries. Anesiva is seeking to license Zingo as well as the underlying drug delivery technology and intellectual property.